F2RL1 and Lynch syndrome: Similarly, OC’s suppression of pro-tumorigenic inflammatory pathways (e.g., PAR-2, NF-κB, STAT3) suggests its utility for Lynch syndrome patients and other high-risk groups with chronic inflammation.